Oxford Nanopore Technologies (LSE:ONT), which develops nanopore-based molecular sensing technology for DNA and RNA sequencing, said the Munich Local Division of the Unified Patent Court has granted a preliminary injunction against MGI Tech GmbH.
The ruling covers MGI's CycloneSEQ-WT02, CycloneSEQ-WY01, G100-ER and G400-ER sequencer systems, plus any equivalent products using materially the same technology.
Oxford Nanopore brought the application claiming these systems infringe two of its patents, EP 2 422 198 and EP 2 715 343.
The injunction bars MGI Tech from making, marketing, importing, storing or supplying the affected systems and related flow cells in Denmark, France, Germany, the Netherlands, Liechtenstein, Switzerland, the UK and Ireland, with the Irish order to systems used with a flow cell.
The order took effect immediately and remains enforceable pending any appeal, with penalty payments attached for non-compliance.
Oxford Nanopore will now pursue a permanent injunction, with the Court scheduling the trial hearing for October 2027.
The company said it regards its intellectual property, protected through a global patent portfolio, as fundamental to delivering value for customers, partners and shareholders.
News Intelligence what this means for the company
Oxford Nanopore secured a preliminary injunction from the Munich Local Division of the Unified Patent Court barring MGI Tech from selling four CycloneSEQ and G-series sequencer systems across eight European jurisdictions (Denmark, France, Germany, the Netherlands, Liechtenstein, Switzerland, the UK and Ireland), effective immediately, based on infringement of two Oxford Nanopore patents. The ruling protects Oxford Nanopore's core IP in a competitive sequencing market and removes a direct competitor's product access to a major region pending a permanent injunction trial scheduled for October 2027.
The injunction validates Oxford Nanopore's patent portfolio and removes near-term competitive pressure from MGI Tech in Europe, a material market for sequencing instruments. This de-risks the company's IP moat at a time when its 2026 EV/sales of about 3.3x trades at a substantial discount of roughly 40–50% to peer sequencing companies, though the outcome of the October 2027 trial and any appeal remains uncertain.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
